首页> 外文期刊>Journal of molecular medicine: Official organ of the "Gesellschaft Deutscher Naturforscher und Arzte." >Clinical variability in distal spinal muscular atrophy type 1 (DSMA1): determination of steady-state IGHMBP2 protein levels in five patients with infantile and juvenile disease.
【24h】

Clinical variability in distal spinal muscular atrophy type 1 (DSMA1): determination of steady-state IGHMBP2 protein levels in five patients with infantile and juvenile disease.

机译:1型远端脊髓性肌萎缩症(DSMA1)的临床变异性:确定5例婴儿和青少年疾病患者的稳态IGHMBP2蛋白水平。

获取原文
获取原文并翻译 | 示例
           

摘要

Distal spinal muscular atrophy type 1 (DSMA1) is caused by mutations in the immunoglobulin mu-binding protein 2 (IGHMBP2) gene. Patients with DSMA1 present between 6 weeks and 6 months of age with progressive muscle weakness and respiratory failure due to diaphragmatic palsy. Contrary to this "classic" infantile disease, we have previously described a DSMA1 patient with juvenile disease onset. In this paper, we present (1) a second juvenile case and (2) the first study of DSMA1 on protein level in patients with infantile (n = 3) as well as juvenile (n = 2) disease onset observing elevated residual steady-state IGHMBP2 protein levels in the patients with late onset DSMA1 as compared to those with classic DSMA1. Mutation screening in IGHMBP2 revealed two patients compound heterozygous for a novel missense mutation (c.1478C-->T; p.T493I) and another previously described mutation. In lymphoblastoid cells of both patients, steady-state IGHMBP2 protein levels were reduced. In comparison to wild-type IGHMBP2,the p.T493I variant protein had an increased tendency to aggregate and spontaneously degrade in vitro. We verified a change in the physicochemical properties of the p.T493I variant which may explain the pathogenicity of this mutation. Our data further suggest that the age of onset of DSMA1 is variable, and we discuss the effect of residual IGHMBP2 protein levels on the clinical course and the severity of the disease.
机译:远端脊髓性肌萎缩症1型(DSMA1)是由免疫球蛋白mu结合蛋白2(IGHMBP2)基因突变引起的。 DSMA1患者的年龄在6周至6个月之间,由于diaphragm肌麻痹而进行性肌无力和呼吸衰竭。与这种“经典”婴儿疾病相反,我们先前已经描述了一名DSMA1患青少年疾病的患者。在本文中,我们介绍了(1)第二例青少年病例(2)对DSMA1在婴儿(n = 3)和青少年(n = 2)发病时观察到的残留稳定水平升高的蛋白质水平的首次研究。与经典DSMA1相比,晚期DSMA1患者的IGHMBP2蛋白水平升高。在IGHMBP2中进行的突变筛选显示,两名患者为新的错义突变(c.1478C-> T; p.T493I)为复合杂合子,而另一名先前描述为突变。在两名患者的淋巴母细胞中,稳态IGHMBP2蛋白水平均降低。与野生型IGHMBP2相比,p.T493I变异蛋白在体外具有聚集和自发降解的趋势。我们验证了p.T493I变体的理化性质的变化,这可能解释了此突变的致病性。我们的数据进一步表明DSMA1的发病年龄是可变的,我们讨论了残留的IGHMBP2蛋白水平对临床病程和疾病严重程度的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号